Home › Castration-Resistant Prostatic Cancer › NCT07677254

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform

Who can join

Ages 18 to 115 · Men

Inclusion criteria:

* Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
* Male sex at index, where index is the date of initial mCRPC diagnosis.
* Age 18 years at index.

Exclusion criteria:

• None

About the study

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Sponsor: Novartis Pharmaceuticals · Participants: 17,111 · Started: Jun 30, 2026

Contact the study team

• Novartis Pharmaceuticals · Phone: +41613241111

Official record on ClinicalTrials.gov — NCT07677254

Locations in the U.S.

Conditions

• Castration-Resistant Prostatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.